001     144635
005     20240229123019.0
024 7 _ |a 10.1093/jnci/djz166
|2 doi
024 7 _ |a pmid:31435679
|2 pmid
024 7 _ |a 0027-8874
|2 ISSN
024 7 _ |a 0198-0157
|2 ISSN
024 7 _ |a 1460-2105
|2 ISSN
024 7 _ |a altmetric:65441327
|2 altmetric
037 _ _ |a DKFZ-2019-02077
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 0
|e First author
|u dkfz
245 _ _ |a Pre-diagnostic plasma bile acid levels and colon cancer risk: A prospective study.
260 _ _ |a Oxford
|c 2020
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1601380253_10578
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 May 1;112(5):516-524#EA:C020#LA:C020#
520 _ _ |a Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans.Associations between pre-diagnostic plasma levels of 17 primary, secondary and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations.Positive associations were observed between colon cancer risk and plasma levels of 7 conjugated bile acid metabolites, i.e. primary bile acids glycocholic acid (ORQuartile 4 vs. Quartile 1=2.22,95 % confidence interval[CI]=1.52, 3.26), taurocholic acid (OR = 1.78, 95%CI=1.23, 2.58), glycochenodeoxycholic acid (OR = 1.68, 95%CI=1.13, 2.48), taurochenodeoxycholic acid (OR = 1.62, 95%CI=1.11-2.36), and glycohyocholic acid (OR = 1.65, 95%CI=1.13, 2.40) as well as the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95%CI=1.12, 2.54) and taurodeoxycholic acid (OR = 1.54, 95%CI=1.02, 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk.This prospective study showed that pre-diagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Stepien, Magdalena
|b 1
700 1 _ |a López-Nogueroles, Marina
|b 2
700 1 _ |a Machado, Antje Damms
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Sookthai, Disorn
|0 P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be
|b 4
|u dkfz
700 1 _ |a Johnson, Theron
|0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
|b 5
|u dkfz
700 1 _ |a Roca, Marta
|b 6
700 1 _ |a Hüsing, Anika
|0 P:(DE-He78)6519c85d61a3def7974665471b8a4f74
|b 7
|u dkfz
700 1 _ |a Maldonado, Sandra González
|b 8
700 1 _ |a Cross, Amanda J
|b 9
700 1 _ |a Murphy, Neil
|b 10
700 1 _ |a Freisling, Heinz
|b 11
700 1 _ |a Rinaldi, Sabina
|b 12
700 1 _ |a Scalbert, Augustin
|b 13
700 1 _ |a Fedirco, Veronika
|b 14
700 1 _ |a Severi, Gianluca
|b 15
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 16
700 1 _ |a Mancini, Francesca Romana
|b 17
700 1 _ |a Sowah, Solomon A
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Boeing, Heiner
|b 19
700 1 _ |a Jakszyn, Paula
|b 20
700 1 _ |a Sánchez, Maria-Jose
|b 21
700 1 _ |a Merino, Susana
|b 22
700 1 _ |a Colorado-Yohar, Sandra
|b 23
700 1 _ |a Barricarte, Aurelio
|b 24
700 1 _ |a Khaw, Kay Tee
|b 25
700 1 _ |a Schmidt, Julie A
|b 26
700 1 _ |a Perez-Cornago, Aurora
|b 27
700 1 _ |a Trichopoulou, Antonia
|b 28
700 1 _ |a Karakatsani, Anna
|b 29
700 1 _ |a Thriskos, Paschalis
|b 30
700 1 _ |a Palli, Domenico
|b 31
700 1 _ |a Agnoli, Claudia
|b 32
700 1 _ |a Tumino, Rosario
|b 33
700 1 _ |a Sacerdote, Carlotta
|b 34
700 1 _ |a Panico, Salvatore
|b 35
700 1 _ |a Bueno-de-Mesquita, Bas
|b 36
700 1 _ |a van Gils, Carla H
|b 37
700 1 _ |a Heath, Alicia
|b 38
700 1 _ |a Gunter, Marc J
|b 39
700 1 _ |a Riboli, Elio
|b 40
700 1 _ |a Lahoz, Agustín
|b 41
700 1 _ |a Jenab, Mazda
|b 42
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 43
|e Last author
|u dkfz
773 _ _ |a 10.1093/jnci/djz166
|g p. djz166
|0 PERI:(DE-600)1465951-7
|n 5
|p 516-524
|t Journal of the National Cancer Institute
|v 112
|y 2020
|x 1460-2105
909 C O |p VDB
|o oai:inrepo02.dkfz.de:144635
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)6519c85d61a3def7974665471b8a4f74
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 43
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JNCI-J NATL CANCER I : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b JNCI-J NATL CANCER I : 2017
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 0 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21